Small Cap Feast
Small Cap Feast – 17 June 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
Bagir Group has left AIM after entering liquidation. Indigovision has left AIM after being acquired
Bagir Group has left AIM after entering liquidation. Indigovision has left AIM after being acquired
What’s Cooking in the IPO Kitchen?
The pantry is bare!
MediaZest* 0.0425pp £0.6m (MDZ.L)
MediaZest has been awarded two new projects, one from an existing client and one from a new client .
The Projects, which are in the Corporate and Retail sectors respectively, will generate revenue of £125,000 for the Group at a minimum, with additional revenue expected from each. Completion of both Projects is anticipated in August 2020.
The Board continues to receive new client briefs as companies emerge from the lockdown and will provide shareholders with further updates regarding new business opportunities for MediaZest as appropriate.
Thor Mining* 0.37p £4.5m (THR.L)
Q&A document which reflects some of the questions received from shareholders following the Company’s recent announcements in respect of the proposed acquisition of uranium & vanadium focussed claims in the USA. Notes that the funds raised in the recent placement, and the funds expected from the forecast sale of the Spring Hill royalty entitlement are expected to be sufficient to meet the envisaged project expenditure for these new assets, and also our copper, gold, tungsten and molybdenum projects for the balance of this calendar year.
Outlines positive dynamics in the Uranium market, states that the assets’ project claims are in an area of historical high grade production. There is a processing plant close by, which; a. Has significant spare capacity and b. Has historically acquired and / or toll treated ore from mines in the region for processing and conversion into saleable uranium and vanadium concentrates. Gives an outlook on the rest of the diversified portfolio which includes quite advanced copper, tungsten and molybdenum projects and some early stage gold projects.
Pelatro 48.5p £15.8m (PTRO.L)
AGM Update. Current trading — “As noted in our announcement of 8 April 2020, we continue to see “business as usual” and it is pleasing to report that the Group’s activities have been minimally impacted by the coronavirus pandemic. Most of our employees continue to work from home, with a small number working from our offices in India, where the lockdown restrictions have been partially lifted. Despite the additional scrutiny of any investment decision due to the pandemic, our customers continue to invest in our solutions, which allow them to reach their subscribers directly. Demand for Pelatro’s solutions has not flagged and, as a result of various new contracts, including Change Requests and new “modules” our revenue visibility for 2020 has increased to US$5.0m and Annualised Recurring Revenue (ARR) to $4.7m.”
Evgen Pharma 11.05p £14.7m (EVG.L)
The clinical stage drug development company, announced participation in the recently notified funding initiative for COVID-19 clinical trials by the medical research charity, LifeArc. Under this scheme Evgen’s lead product candidate, SFX-01, has been selected for evaluation in a randomised Phase II/III trial to be sponsored by the University of Dundee. The trial will investigate whether SFX-01 can reduce the severity, or prevent the onset of, acute respiratory distress syndrome associated with COVID-19, thus reducing the need for invasive patient ventilation and potentially improving recovery times.
SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. Preclinical studies have shown that up-regulating the Nrf2 pathway reduces the severity of ARDS, the progressive lung damage observed in COVID-19 patients which can result in the need for invasive ventilation in an intensive care unit.
XL Media 22.75p £42.6m (XLM.L)
The global digital performance publisher, announced the appointment of Ken Dorward to its Global Executive Committee as President – North America. XLMedia is currently consolidating and rebalancing its publishing portfolio, with a greater emphasis on regulated and high-potential markets, to deliver more sustainable and predictable growth. This key appointment is aimed at accelerating the Company’s progress outside Europe, with a particular focus on the significant opportunity in North America in the Personal Finance and Sports markets. Most recently Ken was COO and CFO of Rakuten Advertising, a performance marketing, media and data insights subsidiary of Rakuten Inc.
The Panoply Holdings 75p £41.6m (TPX.L)
The technology-enabled services group focused on digital transformation, announces that it is now able to disclose that its subsidiary FutureGov has won a strategically significant contract with the Ministry of Housing, Communities and Local Government (MHCLG), as part of the £9.5 million of new business wins in the first 8 weeks of the current year that the Group announced on 26 May 2020. The project will enable local authorities across England to access the £3.6 billion ‘Towns Fund’, a fund that will be invested into 100 towns as part of the government’s plan to level up the UK’s regions.
Panthera Resources 4.75p £4.02m (PAT.L)
The gold exploration and development company with assets in India and West Africa, has entered into a new term sheet which extends the partnership entered into with Galaxy Gold Mines Pvt Limited as announced on 20 December 2018.
Unless further extended, the new term sheet with Galaxy will terminate on 16 December 2020. Galaxy providing administrative, legal, permitting and technical support in India that will allow it to potentially earn up to an additional 12% equity in IGL upon achieving certain success hurdles in the lead up to the commencement of mining at the Bhukia Project.
Science Group 225p £93.4m (SAG.L)
Science Group has appointed Peter Bertram to the Board of Directors as Non-Executive Director with effect from 17 June 2020. Mr Bertram will also Chair the Audit Committee and be a member of the Remuneration and Nomination Committees.
Mr Bertram is currently Chairman of Manolete Partners plc and a Non-Executive Director of Low & Bonar plc. He has previously held a variety of Non-Executive board positions including Alphameric plc, Anite plc, Microgen plc, Phoenix IT group plc and Psion plc, and was CEO of Azlan Group plc. Mr Bertram is a Chartered Accountant and has a degree in Accounting from the University of Kent.
Metal Tiger 2.175p £33.1m (MTR.L)
Notes the Drilling Operations Update released by Southern Gold Limited earlier today. Metal Tiger has a 17.1% equity interest in Southern Gold.
Highlights from Southern Gold’s announcement:
All three diamond drill holes completed at the Aphae Project intersected significant sulphide and/or silica flooded vein breccia and base metal sulphide veining intersected, assays pending.
A wider than expected interval of sulphide-rich breccia zone in APDD003 at Aphae has resulted in an additional diamond drill hole targeting down dip of this zone.
Multiple zones of dynamic polyphasal low-sulphidation epithermal veining were intersected at ‘Hand of Faith’, Beopseongpo, but only returned a peak of 0.24m @ 1.71g/t gold from 139.97m in BPDD013.
Assays expected from the drill program at ‘Spider’, Beopseongpo in early July.
Diamond drilling ongoing at ‘Shin Hill’, Deokon Project.
Tekcapital 12.5p £11m (TEK.L)
The UK intellectual property investment group focused on creating marketplace value from university technology, announces that its portfolio company Belluscura plc is making good progress with its 510K submission though it has been impacted by COVID-19 associated external supply chain issues which has increased the scarcity of certain key components, increased lead times, and reduced capacity at part manufacturers and testing facilities. Belluscura is in the process of completing the final surety tests and anticipates it will receive 510K clearance within H2.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.